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I, INfRODUCTtON 
Proliferation OF cultured cells is controlled by pro- 
teins able to stimulate or inhibit cell growth. A number 
of growth Factors and growth inhibitors has been 
described, and several mitogenic signalling pathways 
have been elucidated [ 11, Heparin is known to interFere 
with the control of cell proliferation [2-41; its effects, 
however, range From stimulation to inhibition, depcnd- 
ing on cell lineage, growth Factor equirement and ex- 
perimental conditions [5-71. It has been proposed that 
stimulation of endothelial cell growth by hcparin is due 
to interaction with specific growth factors, thus stabiliz- 
ing their binding CO receptors [$I. Inhibition of smooth 
muscle cell proliferation has been ascribed to interac- 
tion with growth factors, receptors, or intracellular 
signalling [9-121. We showed that inhibition of serum- 
induced DNA synthesis in BC3H-1 cells was accom- 
panied by inhibition of stimulated inositol lipid turn- 
over [13]; this observation indicated that heparin could 
interfere with the mitogenic signalling cascade activated 
by growth factors. 
However, the effect of heparin on cell proliferation 
has been mainly studied in normal cells which were 
dependent on exogenous growth factors for proiifera- 
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tion and survival. Searching for a mechanism OF action 
that could elucidate the role of hcparin as growth in- 
hibitor, we decided to study its effect on A431 human 
cpidermoid carcinoma cells which grow in the absence 
of serum and ovcrexpress the EGF receptor [14]. 
Another rationale for choosing A431 cells lay in the 
observation that heparin does not bind EGF or its 
receptor [9], thus ruling out the possibility that heparin 
might inhibit cell growth simply by ‘subtracting’ rowth 
factors from the medium. 
2, MATERIALS AND METHODS 
[“H]heparin, [JH]thyn~idinc and [‘W]ntyo-inositol wcrc purchased 
from New England Nuclear Different heparins, heparin fragments, 
and dcrmatan sulfate OP 435 were provided by Opocrin Research 
Laboratories (Modena, Italy). Heparins HP 756 and sm 102G were ex- 
tracted from bovine intestinal mucosa. Low rnolccular weight heparin 
(LMW) (21231850) was obtained by peroxldative cleavage of bovine 
hcparin. Very low molecular weight heparin (VLMW) (1027145) was 
obtained by fractionation on Sephacryl S-200 of a low molecular 
weight heparin (LMW 8X6-87/12OP -av. M.W, 5,OkDa). Molecular 
weights (kDa) were determined by polyacrylamide gel electrophoresis 
[15]+ The degree of sulfatation was evaluated by potentiometric 
analysis, and expressed as molar ratio of sulfate (SOT) and carboxyl 
(COO - ) grong?s determined for each compound [ 161. Activated par- 
tial thromboplastin time (APTT) was measured according to Basu et 
al. and expressed as U/mg [17]. Anti-activated coagulation Factor X 
(AXa) activity was tested in a chromogenic assay as described by 
Teien et al ., and expressed as U/mg [ 181. A summary of the properties 
of these compounds is given in Table I. Hyaluronic acid (from human 
umbilical cord), chondroitin sulfate B, and C (from shark cartilage) 
were from Sigma. Tissue culture media were from Gibco. Bradykinin 
was from Calbiochem. EGF (purified, receptor grade) was from Col- 
laborative Res. A431 human epidermoid carcinoma cells were kindly 
donated by Dr Bruni, lstituto di Chimica Biologica, Florence, Italy. 
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t3r ~timfatit3t7 (SUi KQO 1 ) ir cxprcrrcd nls nrolnr rapid or rulrnrcTgntl 
crrbaxyl groups ctctcrminrtl h each zomp0rirrd [lb). Aciivaicd 
ptlrlinl Ihruinbeplasiin iimc:IhPTT) ir expnrwd 86 l&my [17], hrrti~ 
11~ih1~d eor&ulallnn l%c~ar .Y (A%) aciivhy wtt$ 1ertctl in a 
ehramoWtlie assay and is rxproacd as IJAny [ll%J. Abbreviations 
used: HP. hcp~rln; sin, slow mevin); LMW, low molceulnr wci&; 
KMW, very law nralcculrr rvciphl: RS, dcrmnran sulktie, 
Cell growth wax nsxrxsctl as [‘H]thymidinc insarpamtion. Siudirx 
on thymidine incorpararion wcrc performed by adding ('fi~ll~yniicli~v2 
(0.5 pCi/mI) to ihc CII~III~C~ Ior I II. Al Ihc end or the incubnrlun 
pcriotl, rhc medium was rcmavcd and radiottctlvii~ incorporated hit0 
TCA-prceipitnble marrrial was caunfcd. The rnti~pralilkrrrive cllret 
of difrcrent ylycor~minaglyenns war dctermincd by otlding each corn. 
pound 24 h bcrorc pulse Inbelling. The cffcsi al’ EGF und hcpnrin on 
DNA aynthcsia cells was studied in cMlusnt and xrmi~eanlluem 
cultures,. routinely grown in 17.mni dishes wiilr IN0 FCS. Arlcr 14 I\ 
of strum stnrvniian, the cutrurcs were rcpcnicdly washed wiih rrrnh 
medium (DMEM) and incubaicd for 2-I h with EC;H nnd/or hcpnrin 
GS indicatctl. AI Ihc end of incubniion, [‘W]Ihymidinc (0.5 &3/ml) 
was added for I h, and insorporaiion war; a%sesuxJ. 
Binding csperinicnrs were pcrformctl CSSUlliilllp as previously 
dcscribcd [2j. Briefly, IO cvnlu;~c Ilrc K,l, confluenr culiurrs \vcrc 
washed with cold PBS and prccoolcd ni 4’C for 30 min, Incrcnsiny 
conccnlrntions of (‘H]heparin (7.5-30 nh4) without \~nli~bdlctl 
hcparin, and [‘Hlhcparin (30 nM) with increasing conccnlrntions of 
unlabellcd hcparin (HP 756, iO- 100 nM), WBS added and cells were in. 
cubatcti at 4°C for 2 h. The reaction was sroppcd by removing the ina 
cubarion medium; cells were collected from the dishes onto GF/C 
filters (Whatman) and washed 5 times with cold PBS (5 ml), Fihcrs 
were dried and counted for ‘H-radioactivity, Unspecific binding was 
negligible. Binding specificity of [“Hjhcparin was studied incubaring 
confluent cultures with [“H]heparin for 2 h at 4’C, with or without 
adding lOO.fold escess of unlabellcd glycosaminoglycans. 
Analysis oj hiosirol lipid wnovw 
The effect of heparinon basal and stimulated inositol lipid turnover 
was monitored as accumulation of [‘H]inositol phosphates in cells 
prelabelled with [3H],rlyo-inositol (10 &X/ml) for 48 II. Heparin was 
added either during labelling (24 or 1 h before the experiment), or 
concomitantly with stimuli (EGF or bradykinin), At the end of in- 
cubation, cultures were washed extensively to remove unincorporated 
[3Hjnjyo-inositol and, when present, heparins added 24 or 1 h earlier, 
lnositol phosphates were extracted with chloroform/methanol and 
separated by ion-exchange chromatography [2]. 
3. RESULTS AND DISCUSSlON 
The effect of heparin and Qther &‘CQsamlnO&CNl§ 
on cell proliferation was assessed by measuring 
[jH]thymidine incorporation in cells cultured for 24 h in 
the presence of these compounds. Fig. 1 shows that 
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molecular weight hcparins (HP 756, sm 1026); low 
molecular weight heparin (LMW 212Y850) had in- 
tcrmcdiate efficacy, and very low molecular weighr 
heparin (VLMW 1027/45) was ineffective, Qualitative- 
ly identical results were obraincd by assessing rowth 
inhibition as the decrease of cell numbers, These results 
indicate that the molcculnr weight of hepsrin was 
directly related to growth inhibition. Since the 
molecular weight of hcparin is known to influence its 
binding to the cell surface (21, WC measured binding as 
monitored by displacement of [‘H]hcparin (Fig. 1). The 
calculated Kd value for high molecular weight hcparin 
(HP 756) was 1 x IO - 'I rnol/l. Low molecular weight 
heparin bound less efficiently, and very low molecular 
weight heparin did not bind to the cell surface. In order 
to determine specificity of binding, we measured 
[3H]heparin displacement by other glycosaminoglycans 
which did not inhibit cell growth (i.e. chondroitin 
sulfate B and C, hyaluronic acid, and dermatan sulfate 
OP 435); none of these compounds was able to displace 
bound [3H]hepariti, thus demonstrating that hcparin 
binding to the cell surface was specific for growth in- 
hibitory heparins. 
Experiments reported in Fig. 1 were performed in 
cells grown in the presence of serum. However, since 
transformed cells are able to survive in the absence of 
serum, we decided to study the effect of heparin in 
serurn-starved A431 cells in order to determine whether 
growth inhibition was due to the interaction of heparin 
with nutrients or other factors present in serum. Fig. 2 
shows that heparin significantly inhibited [3H]thy- 
midine incorporation in serum-starved A431 cells for 
HOW6 attrr rtatvrtlon 
up to 60 11 after starvation, Similar results were obrain- 
ed by determining rowth inhibition as the deereasc of 
cell numbers (not shown). These data indicate that 
growth inhibition could not bc ascribed to ‘removal’ of 
essential factors present in the serum, 
Although chc role of EGF as a ‘bona fide’ mitogen in 
A431 cells is rather questionable [14], evidence has ac- 
cumulated that EGF stimulates DNA synthesis in con- 
fluent cultures after 24 h of incubation (14,19). Fig, 3A 
shows that EGF induced significant DNA synthesis 
after 24 h of incubation in confluent cultures, while in- 
hibiting [3H]thymidine incorporation in semi-confluent 
dishes. Consistent with the results shown above, 
heparin inhibited basal (unstimulated) A431 cell pro- 
liferation both in confluent and semi-confluent 
the effecf af heparin on basal and rtirnulafed inosirol 
lipid turnover. A43 I cells over=cxpress the EtJP reeep- 
tar, and addition of EGE results in the hydrolysis of 
phosphoino#iridea [;\a], Hcparin did not affect basal in- 
aska\ lipid turnover (Table II), thus indicating that it 
did not interfere per sc with componcarr of the inoaitide 
pathway. EGP and brndykinin stimulated inorltol llpid 
turnover in A431 cells with the formation of water- 
soluble inositol yhosphatcs (Table II), Hepnrin (1OU 
&ml) did not cause any change in EGF= (50 ng/ml), or 
brndykinin- (1 pM) induced inositol phosphate forma- 
tion in A431 cells, whereas it inhibired serum- 
stimularcd phosphoinositidc hydrolysis in BC3H-1 cells 
[13]. Pretreatment of cells with hcparin for 24 or 1 h, 
folIowed by extensive washing, did not modify the pat- 
tern of EGF-, or bradykinin-induced inositol lipid tur- 
nover. Please note that, in order to detect any possible 
effect of heparin on agonist-stimulated inosirol lipid 
metabolism, we used a concentration of hcparin IO-Fold 
higher than chat used to inhibit cell growth (Fig. 1), or 
EGF-induced chymidine incorporation (Fig. 3). Inhibi- 
tion of serum-induced inositol phosphate formation, 
however, was observed with IO &ml OF heparin [2]. 
Heparin is known to have other effects beside inhibi- 
tion of blood coagulation. Interference with cell growth 
has been described in several systems, but the overall 
picture is confused as heparin has been reported to 
stimulate and/or inhibit proliferation in different cell 
types and under different experimental conditions 
[5-‘71. Also it is not clear which component(s) of the 
mitogcnic signalling cascade are affected by heparin; in- 
Control LGF HP 756 HP&Xl= 
Fig. 3, Effect of EGF and heparin on [“Hlthymidinc incorporation in A431 cells. Serum-starved confluent and semi-confluent A431 cells were 
stimulated with EGF (50 ng/mij, with or without heparin (W 756, IO @g/ml), for 24 h. [3H]thymidine was then added for 1 h. A. Results are 
expressed as dpm of incorporated [‘Hlthymidine, and are means c SE ()z - 4) of an experiment representative of three others which gave 
qualitatively identical results. B. Results are expressed as % increase of EGF-induced [3H]thymidine incorporation in confluent A431 cells. Basal 
ValUeS (i.e. no EGF addition: indicated in the Figure as 100%) of [‘Hlthymidine incorporation were: control, 755602 3245; HP 756, 9154 1423, 
dpm, means k SE (n=4). 
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